Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS-B study of vutrisiran in ATTR amyloidosis with cardiomyopathy
jRCT2031210402Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR), hereditary transthyretin amyloidosis (hATTR), acquired transthyretin amyloidosis (ATTRwt) and 1 more comparing Vutrisiran arm with Placebo arm (2 arms). Primary endpoint: Composite of all-cause mortality and recurrent cardiovascular events. Started Mar 2021; status: completed.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)hereditary transthyretin amyloidosis (hATTR)acquired transthyretin amyloidosis (ATTRwt)heart failure (HF)
Beyond the preview
Go deeper on jRCT2031210402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210402.